Ranked (Band 1) for Corporate/M&A: Northern California and Southern California, sources say “he is a smart, seasoned transactional expert and negotiator, as well as a polished adviser to executives and the board.”Chambers USA 2017

Charles K. Ruck

New York | Orange County
  • 885 Third Avenue
  • New York, NY 10022-4834
  • USA
 
 

Charles Ruck practices in the Orange County and New York offices. Mr. Ruck's practice focuses on mergers and acquisitions, capital markets, and general corporate and securities matters. He serves as primary outside counsel to a number of public and privately held companies and he regularly represents boards of directors and special committees in complex strategic corporate governance matters. Mr. Ruck is a former member of Latham & Watkins' Executive Committee and Chair of the firm's Strategic Client Initiative.

In the merger and acquisitions area, Mr. Ruck has worked on a variety of transactions including:

  • Public company mergers and tender offers
  • Strategic acquisitions and divestitures involving earn-outs and CVRs 
  • Hostile takeovers
  • Going private transactions

In the capital markets area, Mr. Ruck has handled numerous public and private offerings of both debt and equity securities, representing issuers and underwriters. Additionally, he regularly represents the nation's top investment banks in their capacities as financial advisors, underwriters, and placement agents.

Mr. Ruck has received the following recognition:

  • Recognized as a Recommended Lawyer in the Healthcare: Life Sciences category by The Legal 500 2017-2018

  • Recognized as a Recommended Lawyer in Corporate M&A and Commercial Corporate by The Legal 500 2017-2018

  • The Best Lawyers in America in Mergers and Acquisitions Law for 2012-2018

  • Leading Mergers & Acquisitions lawyer in the US by Chambers Global 2018 (Band 2) and in Southern California by Chambers USA 2018 (Band 1)

  • Law360 MVP in Mergers & Acquisitions in 2015 and 2012

  • The National Law Journal 2015 as an M&A Trailblazer

  • Dealmaker of the Year by The American Lawyer 2013 and highlighted as Dealmaker of the Week 2014

  • Euromoney’s Legal Media Group 2012, 2013, 2015and 2016 as Life Sciences Star

  • The Daily Journal as one of the Top 100 Attorneys in California in 2008 and 2012

  • The New York Times as one of an exclusive group of legal and financial professionals leading the next generation of corporate deal makers

  • California Lawyer as Transactional Attorney of the Year

  • Nightingale's Healthcare News as one of the 12 Outstanding Healthcare Transaction Lawyers

Mr. Ruck formerly served as a clerk to the Honorable David M. Ebel, on the US Court of Appeals for the Tenth Circuit, and as negotiator for the US Trade Representative at the World Trade Organization in Geneva, Switzerland.

 

Mr. Ruck's representative mergers and acquisitions transactions include advising:

  • Allergan (fka Actavis/ Watson) in the US$40.5 billion sale of its Global Generic Pharmaceuticals Business to Teva; its US$25 billion acquisition of Forest Laboratories, its US$8.5 billion acquisition of Warner Chilcott, predecessor company Watson Pharmaceuticals in its US$5.65 billion acquisition of Actavis Group Hf in 2012 after which Watson took the target’s name, its US$1.75 billion acquisition of the Arrow Group in 2009, its US$2 billion acquisition of Andrx Corp. in 2006, its US$184 million acquisition of Makoff R&D Laboratories Inc. in 2000, its related financings and other transactions
  • Ignyta, Inc. in its US$1.7 billion acquisition by Roche 
  • ST Telemedia in CenturyLink's US$34 billion acquisition of Level 3 Communications, Inc. 
  • Digital Realty in its US$7.6 billion acquisition of DuPont Fabros
  • Raptor Pharmaceuticals in its US$800 million acquisition by Horizon Pharma plc 
  • WCI Communities in its US$643 million merger with Lennar Corporation 
  • Receptos in its US$7.2 billion acquisition by Celgene
  • Thoratec in its US$3.4 billion acquisition by St. Jude Medical
  • Amphenol Corp. in its US$1.275 billion acquisition of FCI Asia Pte Ltd.
  • Apollo Global Management and TPG Capital in the formation of Caesars Growth Partners and Caesars Acquisition Corporation and the acquisition of US$2.2 billion in assets from Caesars Entertainment Corporation
  • Avanir Pharmaceuticals in its US$3.5 billion acquisition by Otsuka Pharmaceutical
  • Starbucks Corporation in its US$913 million acquisition of Starbucks Coffee Japan, Ltd.
  • The special committee of independent directors of Griffin-American Healthcare REIT II in its US$4 billion acquisition by NorthStar Realty Finance Corp.
  • Spirit Realty Capital, Inc. in its US$7.4 billion merger with Cole Credit Property Trust II
  • Cadence in its US$1.4 billion acquisition by a subsidiary of Mallinckrodt plc
  • ArthroCare Corporation in its US$1.7 billion acquisition by Smith & Nephew
  • A global public biotechnology company in several acquisitions and other transactions
  • J.P. Morgan as financial advisor in the:
    • US$12.8 billion acquisition by UnitedHealth of Catamaran Corporation
    • US$21 billion sale of Pharmacyclics to AbbVie
    • US$3.3 billion merger of Wright Medical Group and Tornier
    • US$8.6 billion merger of MAA and Colonial Properties Trust
    • US$1.65 billion acquisition of MAKO Surgical Corp. by Stryker Corporation 
    • US$13.6 billion acquisition by Thermo Fisher of Life Technologies 
    • US$4 billion acquisition of Gambro AB by Baxter International 
    • US$2.6 billion merger of Covidien and ev3 
    • US $3.6 billion acquisition of King Pharmaceuticals by Pfizer Medicis Pharmaceutical in the US$2.6 billion acquisition by Valeant Pharmaceuticals
  • Goldman, Sachs & Co. in the US$7 billion acquisition of Amylin Pharmaceuticals by Bristol-Myers Squibb
  • Multimedia Games in its US$1.2 billion acquisition by Global Cash Access Holdings
  • Quest Software in its US$2.4 billion acquisition by Dell
  • Harrah’s Entertainment in its US$28 billion sale to affiliates of Texas Pacific Group and Apollo Management, its US$10.3 billion acquisition of Caesars Entertainment and other transactions
  • Complete Production Services in its US$6.2 billion merger with Superior Energy Services
  • American Medical Systems Holdings in its US$2.9 billion sale to Endo Pharmaceuticals Holdings
  • ICOS Corporation in its US$2.3 billion sale to Eli Lilly
  • Hydril Company and its controlling shareholders in its US$2.2 billion sale to Tenaris S.A.
  • First Health Group Corp. in its US$1.9 billion acquisition of Coventry Health Care
  • Adecco in its US$1.3 billion acquisition of the MPS Group
  • Cougar Biotechnology in its US$1 billion sale to Johnson & Johnson
  • Bank of America Merrill Lynch in the US$15.6 billion acquisition of MedImmune, Inc. by AstraZeneca , the US$11 billion acquisition by Gilead Sciences of Pharmasset, and the US$10 billion merger of Federal Express and Kinko’s
  • Morgan Stanley in the US$8.1 billion merger of PacifiCare Group with UnitedHealth Group, creating one of the largest managed care and benefits companies
  • Morgan Stanley in the $1.35 billion sale of UTi Worldwide to DSV
  • Goldman, Sachs & Co. in the US$2.8 billion sales of Advanced Medical Optics to Abbott and the US$6.2 billion acquisition of Cytyc Corporation by Hologic
 
 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.